Search

Displaying results 4021 - 4030 of 7503 in total
  1. Drug

    1D09C3

    go.drugbank.com/drugs/DB05121
    Experimental

    class II-positive tumor cells, which include those in B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a functioning immune system for its cell-killing … The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodies. 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC

  2. Drug

    Gliquidone

    go.drugbank.com/drugs/DB01251
    Approved

    Gliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. … This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.

  3. Drug

    Tildrakizumab

    go.drugbank.com/drugs/DB14004
    ApprovedInvestigational

    A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects [A32257]. … The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

  4. Drug

    7MW3711

    go.drugbank.com/drugs/DB19298
    Investigational

    Developed by Mabwell, 7MW3711 is an antibody-drug conjugate targeting B7-H3.[L50918,L50923]

  5. Drug

    IR208

    go.drugbank.com/drugs/DB05106
    Investigational

    IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation. … It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.

  6. Drug

    Rifalazil

    go.drugbank.com/drugs/DB04934
    Investigational

    It is being investigated by ActivBiotics for the treatment of various bacterial infections.

  7. Drug

    CIGB 2020 Vaccine

    go.drugbank.com/drugs/DB15808
    Experimental

    The vaccine was developed and tested by the Center for Genetic Engineering and Biotechnology (CIGB), in Havana Cuba. … CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered.

  8. Drug

    Tegoprazan

    go.drugbank.com/drugs/DB16690
    Investigational

    Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases. … [A234215, A234220] Tegoprazan’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels.

  9. Drug

    Interferon Gamma

    go.drugbank.com/drugs/DB15753
    Investigational

    The interferon is primarily produced by activated T lymphocytes and natural killer cells.

  10. Drug

    alpha-Hydroxy glycineamide

    go.drugbank.com/drugs/DB06568
    Experimental

    Alpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid … It also has an effect on viral gp160 envelope protein. [A31692]